Skip to content

The effects of digital health intervention on the clinical prognosis of ST elevation myocardial infarction (DHI-STEMI)

The effects of digital health intervention on the clinical prognosis of ST elevation myocardial infarction (DHI-STEMI)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081156
Enrollment
Unknown
Registered
2024-02-23
Start date
2024-02-24
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

experimental group:Digital management after PCI procedure

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the STEMI diagnostic criteria and are planned to undergo PCI; 2.Aged =18 years and =70 years, regardless of gender; 3.First-time undergoing PCI; 4.Voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Individuals with serious illnesses and an expected lifespan of less than 1 year; 2.People with disabilities using smartphones; 3.Co-existing malignant tumors; 4.Combined with severe liver and kidney dysfunction(ALT or AST exceeding 3 times the upper limit of normal range(ULN),TBil>1.5mg/dl) Abnormal renal function(eGFR<30ml/min/1.73m2); 5.Mental abnormalities or mental illness, unable to cooperate with management; 6.History of severe intracranial vascular disease: cerebral aneurysm, hemorrhagic stroke, intracranial tumor, ischemic stroke within 6 months/transient ischemic attack; 7.=50% stenosis of the left main coronary artery; 8.Previous cardiac surgery patients: coronary artery bypass grafting, congenital heart disease surgery, valve replacement, heart transplantation, radiofrequency ablation, pacemaker implantation, etc.; 9.Complicated with a bleeding disorder:hemophilia, leukemia, purpura caused by various reasons, etc.; 10.Participants in other drug clinical trials in the past year.

Design outcomes

Primary

MeasureTime frame
Cumulative Incidence of Major Clinical Events;Revised Revascularization;Hospitalization for Heart Failure;Stroke;Cardiovascular Death and All-Cause Death;

Secondary

MeasureTime frame
Recurrent Angina;Blood Pressure and Heart Rate and LDL-c Control Rate;Gastrointestinal/Cerebrovascular Hemorrhagic Events;Patient Satisfaction;Quality of Life;

Countries

China

Contacts

Public ContactZHANG JINYING

The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Dong Road, Erqi District, Zhengzhou

jyzhang@126.com+86 135 0383 0283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026